Medicare Enrolled
Dr. Jaya Juturi, MD
Hematology & Oncology · Dallas, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Mixed engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Juturi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Juturi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Juturi
Dr. Jaya Juturi is a hematology & oncology specialist in Dallas, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Juturi performed 80,536 Medicare services across 4,230 unique beneficiaries.
Between the years covered by Open Payments, Dr. Juturi received a total of $2,582 from 22 pharmaceutical and/or device companies across 39 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Juturi is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 11% volume in TX
$2,582 industry payments
Medicare Practice Summary
Medicare Utilization ↗80,536
Medicare services
Top 11% in TX for hematology & oncology
4,230
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~4,027 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
14,800 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
13,650 | $0 | $5 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
12,090 | $2 | $20 |
| Pembrolizumab injection (Keytruda) | 10,100 | $42 | $137 |
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
6,700 | $0 | $33 |
| Paclitaxel chemotherapy injection | 6,018 | $0 | $8 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,627 | $0 | $1 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
1,370 | $21 | $181 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,230 | $1 | $114 |
| Bevacizumab-bvzr biosimilar injection, 10 mg An injection of bevacizumab-bvzr, a biosimilar medication, administered in a 10 mg dose. |
1,130 | $24 | $155 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,121 | $8 | $20 |
| Immune globulin infusion (Octagam) This procedure involves the administration of immune globulin medication directly into a vein. It is provided in a non-lyophilized liquid form. |
1,070 | $33 | $233 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,043 | $8 | $36 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
1,002 | $10 | $64 |
| Injection, granisetron hydrochloride, 100 mcg | 950 | $0 | $24 |
| Injection, atropine sulfate, 0.01 mg | 840 | $0 | $1 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
440 | $87 | $368 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
368 | $23 | $157 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
313 | $102 | $707 |
| Injection, irinotecan, 20 mg | 301 | $2 | $210 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
293 | $2 | $13 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
277 | $2 | $300 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
264 | $82 | $1,348 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
243 | $137 | $496 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
216 | $6 | $431 |
| Immunoglobulin level test A blood test that measures the level of gammaglobulins, which are immune system proteins. |
171 | $9 | $56 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
148 | $12 | $108 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
146 | $50 | $313 |
| Injection, potassium chloride, per 2 meq | 145 | $0 | $1 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
134 | $13 | $60 |
| Iron level test | 134 | $6 | $27 |
| Iron binding capacity test A blood test that measures the amount of iron in the blood and the blood's ability to bind and transport iron. |
134 | $9 | $35 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
132 | $11 | $96 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
132 | $2 | $19 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 130 | $3 | $373 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
113 | $1 | $7 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
109 | $23 | $161 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
95 | $52 | $344 |
| Immunoglobulin light chain measurement A blood test that measures the levels of immunoglobulin light chains, which are proteins produced by plasma cells. |
90 | $17 | $60 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
90 | $1 | $6 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
89 | $6 | $31 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
88 | $71 | $70 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
82 | $19 | $99 |
| New patient office visit, complex (60-74 min) | 81 | $164 | $709 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 80 | $20 | $128 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
64 | $1 | $8 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
55 | $4 | $22 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
54 | $6 | $34 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
53 | $58 | $211 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
51 | $1 | $19 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
48 | $16 | $100 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
46 | $26 | $256 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
43 | $56 | $250 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
42 | $10 | $75 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 38 | $135 | $3,675 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
37 | $27 | $145 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
31 | $94 | $357 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
31 | $135 | $500 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
27 | $136 | $694 |
| Injection, lorazepam, 2 mg | 25 | $1 | $3 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
21 | $15 | $96 |
| Echocardiogram, transthoracic An ultrasound of the heart that uses color to show blood flow, rate, direction, and valve function. |
20 | $110 | $805 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
20 | $121 | $565 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
20 | $62 | $247 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
18 | $30 | $247 |
| Automated red blood cell count with calculations A blood test that automatically counts red blood cells and performs additional calculations to assess blood health. |
13 | $5 | $26 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
2.8% high complexity
90.5% medium
6.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,582
Total received (2018-2024)
Avg $369/year across 7 years
Bottom 46% in TX for hematology & oncology
22
Companies
39
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$910 (35.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$734 (28.4%)
Other
Charitable contributions, space rental, and other categories
$549 (21.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$389 (15.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$485
2023
$369
2022
$1,505
2021
$125
2020
$20
2019
$28
2018
$50
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Genentech USA, Inc.
$910
Novartis Pharmaceuticals Corporation
$412
Lilly USA, LLC
$363
NOVARTIS PHARMACEUTICALS CORPORATION
$183
Kite Pharma, Inc.
$143
Myriad Genetic Laboratories, Inc.
$115
Alexion Pharmaceuticals, Inc.
$106
Gilead Sciences, Inc.
$56
Incyte Corporation
$49
Janssen Biotech, Inc.
$41
GENZYME CORPORATION
$36
Tempus AI, Inc
$29
ABBVIE INC.
$20
GlaxoSmithKline, LLC.
$17
Daiichi Sankyo Inc.
$17
Karyopharm Therapeutics Inc.
$17
PFIZER INC.
$15
Pharmacyclics LLC, An AbbVie Company
$14
Foundation Medicine, Inc.
$14
E.R. Squibb & Sons, L.L.C.
$11
Celgene Corporation
$11
Clovis Oncology, Inc.
$3
Top 3 companies account for 65.3% of total payments
Associated products mentioned in payments ›
CARVYKTI · CYRAMZA · DARZALEX · ELIQUIS · ERLEADA · Enhertu · FOUNDATIONONE · Imbruvica · JAKAFI · KISQALI · OJJAARA · OPDIVO · PIQRAY · Perjeta · PreciseTumor · Rubraca · SARCLISA · ULTOMIRIS · VENCLEXTA · VERZENIO · XPOVIO · Yescarta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (35%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $3 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
131
Per 100K population
5.0
County median income
$74,149
Nearest hospital
TEXAS HEALTH PRESBYTERIAN HOSPITAL DALLAS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Juturi is a mixed practice specialist, with above-average Medicare volume (top 11% in TX), with mixed engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Juturi experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Juturi performed 14,800 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Juturi receive payments from pharmaceutical companies?
Yes. Dr. Juturi received a total of $2,582 from 22 companies across 39 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Juturi's costs compare to other hematology & oncology specialists in Dallas?
Dr. Juturi's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Juturi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Dallas
Browse hematology & oncology specialists in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology